BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Type 1 diabetes clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for type 1 diabetes: 158 (103 sponsors; 37 newly posted in the last 180 days, 2 stopped in the last 180 days; 23 new-entrant sponsors). Momentum score 20.6, rank 27 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 2, Phase 1 36, Phase 2 33, Phase 3 21, Phase 4 2, N/A 64.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Eli Lilly and Company LLY | 9 | P1 4, P3 5 | 2 | 2 |
| Novo Nordisk A/S NVO | 9 | P1 4, P3 3, NA 2 | 2 | 2 |
| AstraZeneca AZN | 5 | P3 3, P1 1, NA 1 | 3 | 1 |
| Vertex Pharmaceuticals Incorporated VERX | 3 | P3 2, P2 1 | 0 | 1 |
| Biocad | 2 | P3 2 | 0 | 1 |
| Viking Therapeutics, Inc. VKTX | 2 | P3 2 | 1 | 0 |
| Sanofi SNY | 9 | P2 3, NA 5, P3 1 | 0 | 3 |
| vTv Therapeutics VTVT | 2 | P2 1, P3 1 | 1 | 1 |
| Oramed, Ltd. ORMP | 1 | P3 1 | 0 | 1 |
| Yong Zhao, MD, PhD | 1 | P3 1 | 0 | 0 |
| Insulet Corporation PODD | 5 | NA 5 | 0 | 2 |
| Medtronic MiniMed, Inc. MDT | 5 | NA 5 | 1 | 2 |
| Helmholtz Zentrum München | 3 | NA 3 | 0 | 0 |
| MedImmune LLC | 3 | P1 2, P2 1 | 0 | 0 |
| Senseonics, Inc. SENS | 3 | NA 3 | 0 | 0 |
| Amgen AMGN | 2 | P1 2 | 0 | 0 |
| Arrowhead Pharmaceuticals ARWR | 2 | P2 2 | 0 | 1 |
| Beta Bionics, Inc. BBNX | 2 | NA 2 | 1 | 0 |
| Encellin | 2 | P1 2 | 1 | 0 |
| GentiBio, Inc | 2 | NA 1, P1 1 | 0 | 1 |
| Kriya Therapeutics, Inc. new entrant | 2 | P2 2 | 2 | 0 |
| mylife Diabetes Care AG | 2 | NA 2 | 1 | 1 |
| Renalytix AI, Inc. RNLXY | 2 | NA 2 | 0 | 0 |
| Abbott Diabetes Care new entrant | 1 | NA 1 | 1 | 0 |
| AC Immune SA ACIU | 1 | P1 1 | 0 | 1 |
New-entrant sponsors: Kriya Therapeutics, Inc., Abbott Diabetes Care.
Recently stopped trials
- NCT04628481 Dompé Farmaceutici S.p.A - terminated: The study was stopped due to futility as per protocol A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function
- NCT05018585 Diamyd Medical AB - terminated: Stopped for futility. A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control i
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Zucara Therapeutics Inc. | NCT05762107 A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes | Type 1 Diabetes Mellitus With Hypoglycemia | recruiting | 186 |
| 2027-01-31 est. | P1/P2 | Creative Medical Technology Holdings Inc CELZ | NCT05626712 Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes | Type 1 Diabetes; Diabetes Mellitus, Type 1 | recruiting | 18 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P3 | Eli Lilly and Company LLY | NCT06962280 A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | Type 1 Diabetes; Obesity; Overweight | active not recruiting | 465 |
| 2026-11 est. | P3 | Eli Lilly and Company LLY | NCT06914895 A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | Type 1 Diabetes; Obesity; Overweight | active not recruiting | 905 |
| 2026-10 est. | P1/P2 | Sernova Biotherapeutics Inc. | NCT03513939 A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation | Type 1 Diabetes Mellitus | active not recruiting | 17 |
| 2026-09-17 est. | P3 | Vertex Pharmaceuticals Incorporated VERX | NCT06832410 An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant | Type 1 Diabetes; Kidney Transplant | recruiting | 10 |
| 2026-06-24 | P3 | Diamyd Medical AB | NCT05018585 A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 D | Type 1 Diabetes Mellitus | terminated | 321 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "type 1 diabetes"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.